MPLT

MapLight Therapeutics Inc

Jan 30 • 04:00PM ET

17.69

-0.89 -4.79 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF VTWO SCHA IWO IWN IWC SCHB RSSL

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	54.98%	Shs Outstand	45.37M	Perf Week	-1.61%
Market Cap	802.65M	Forward P/E	-	EPS next Y	-	Insider Trans	34.22%	Shs Float	20.43M	Perf Month	-1.34%
Enterprise Value	1.09B	PEG	-	EPS next Q	-0.99	Inst Own	1.98%	Short Float	5.31%	Perf Quarter	6.89%
Income	-	P/S	-	EPS this Y	-	Inst Trans	21.84%	Short Ratio	3.87	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	1.09M	Perf YTD	0.71%
Book/sh	-6.04	P/C	3.53	EPS next 5Y	-	ROE	-	52W High	21.55 -17.91%	Perf Year	-
Cash/sh	5.01	P/FCF	-	EPS past 3/5Y	-60.77% -	ROIC	-	52W Low	12.24 44.53%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.02% 9.53%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.55	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.22	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.24	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.22	EPS Q/Q	-41.88%	SMA20	-0.62%	Beta	-	Target Price	31.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	1.45%	Rel Volume	0.93	Prev Close	18.58
Employees	-	LT Debt/Eq	0.02	Earnings	Dec 04 BMO	SMA200	3.62%	Avg Volume	280.17K	Price	17.69
IPO	Oct 27, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-2055.36% -	Trades		Volume	259,634	Change	-4.79%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-25	Initiated	Stifel	Buy	$28
Nov-21-25	Initiated	Morgan Stanley	Overweight	$34
Nov-21-25	Initiated	Leerink Partners	Outperform	$30
Nov-21-25	Initiated	Jefferies	Buy	$32

Jan-09-26 07:00AM	MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 (GlobeNewswire)
Jan-05-26 07:00AM	MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis (GlobeNewswire)
Dec-16-25 07:00AM	SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies (GlobeNewswire)
Dec-04-25 07:00AM	MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress (GlobeNewswire) +8.39%
Nov-07-25 07:26PM	MapLight Therapeutics, Gold Royalty, and More Stocks See Action From Activist Investors (Barrons.com)
09:06AM	Loading…
Oct-29-25 09:06AM	MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-26-25 05:30PM	MapLight Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Malenka Robert C.	Director	Jan 29 '26	Sale	18.55	21,262	394,410	371,885	Jan 30 08:50 PM
Malenka Robert C.	Director	Jan 28 '26	Sale	18.65	6,524	121,704	393,147	Jan 30 08:50 PM
Malenka Robert C.	Director	Jan 30 '26	Sale	18.11	6,612	119,743	365,273	Jan 30 08:50 PM
ROBERT MALENKA	Director	Jan 30 '26	Proposed Sale	18.11	6,612	119,737		Jan 30 04:17 PM
ROBERT MALENKA	Director	Jan 29 '26	Proposed Sale	18.55	21,262	394,470		Jan 29 04:06 PM
ROBERT MALENKA	Director	Jan 28 '26	Proposed Sale	18.65	6,524	121,690		Jan 28 04:20 PM
Novo Holdings A/S	10% Owner	Oct 28 '25	Buy	17.00	952,941	16,199,997	3,686,622	Oct 30 04:31 PM
Catalyst4, Inc.	10% Owner	Oct 28 '25	Buy	17.00	5,441,176	92,499,992	19,697,464	Oct 29 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MPLT

MapLight Therapeutics Inc

Upgrade your FINVIZ experience